Close
Every biotech founder has heard some version of the same advice: investors pay up for platforms, not molecules. Build the story around a technology that can spin out asset after asset, and the multiple takes care of itself. It’s comforting advice, and according to the founders and investors who actually lived it at BIO 2026, it’s also mostly backwards.
At the June 22 panel “Success in a Product-First Market,” five operators and one venture partner described a market that rewards platform narratives almost exclusively in retrospect. Danielle Appelhans built COUR Pharmaceuticals on lead-asset discipline and only got credit for her platform after the lead program moved. Nick Mordwinkin held Trace Neuroscience to a single ALS asset through its 2024 Series A, on the theory that pipeline expansion only becomes credible once you have proof of concept. Frank Taffy described a formal rubric Congruence Therapeutics uses to pick targets, because target selection, not narrative framing, is the highest-leverage decision a company makes.
And then there is Joanna Stanicka, who did the opposite and was right to. Axonis Therapeutics turned down narrower, trial-shaped investment offers, bet on the platform story before a Phase 1B readout existed, and raised more than $150 million doing it.
Both camps won, each correct for its own risk profile. The mistake founders make is treating “platform” versus “asset” as a style choice, a matter of narrative preference, rather than a structural decision that depends on what kind of risk they’re actually asking investors to underwrite. This paper lays out the evidence and gives boards a framework for making that call deliberately, instead of copying whichever version they last saw succeed on a conference stage.
Three data points from the panel make the case that platform credit is awarded after the fact, not in advance.
Danielle Appelhans, president and CEO of COUR Pharmaceuticals, was direct about the sequencing. COUR’s public story is built on immune tolerance, a platform with applications across autoimmune disease, but Appelhans said she only “got credit” for that platform and its supporting data once the lead program had already advanced. The platform was real the whole time; it just wasn’t valued until there was clinical progress to anchor it to. Appelhans’s broader framing of prioritization reinforces the point: she assesses conviction and unmet need through a regulatory and commercial lens (orphan drug status, validated preclinical models, where the highest unmet need sits) and partners out larger indications where someone else’s expertise is a better fit. Right now, COUR is going full steam on type 1 diabetes: a resourcing decision, not a storytelling one, that lets the narrative follow the data rather than the other way around.
Nick Mordwinkin, CBO and chief strategy officer at Trace Neuroscience, described an even more deliberate version of the same discipline. Trace raised its 2024 Series A while staying lead-asset-focused on its antisense oligonucleotide for ALS, deliberately avoiding the distraction of multiple indications. Mordwinkin’s framing of when a company “earns the right” to expand is worth quoting for its precision: proof of concept, not investor appetite, not a compelling deck, and not a platform that theoretically supports six other diseases. Proof of concept in one drug is the toll booth; multiple indications only became a favorable story for Trace after they had it.
Frank Taffy, CBO of Congruence Therapeutics, supplies the mechanism behind that discipline. Congruence, which closed financing led by OrbiMed and has since dosed its first patient in a first-in-human study for MC4-deficient genetic obesity, built an explicit rubric for target selection: incidence, prevalence, competitive intensity, translational models, assay quality. Taffy called target selection the single most important decision a biotech makes. He also drew a useful investor-segmentation line: traditional funds like OrbiMed still underwrite the lead asset, while newer investors are more likely to underwrite the platform and ask about second and third indications. That split matters for the framework below: the “prove first” path isn’t just a founder preference, it’s often a function of which check is being written.
Joanna Stanicka’s story at Axonis isn’t a rebuttal to the prove-first camp; it’s a demonstration that the rule has a boundary condition.
Axonis started in spinal cord injury. Stanicka struggled to raise capital against that indication and faced a real decision: stay the course or pivot to something more translatable. She pivoted. That alone is a lesson in capital discipline: sunk cost in an indication is not a reason to keep funding it.
The sharper lesson is what happened next. Stanicka had investment offers on the table for a narrower, clinical-trial-based story, the kind of single-asset pitch that Mordwinkin and Appelhans would recognize and, on their own logic, might have taken. She turned them down. Her reasoning: betting the company on one asset was too concentrated a risk given how powerful she judged the underlying platform to be. She built the raise around the size of the platform opportunity instead, and closed more than $150 million.
Rejection is not, by itself, evidence that the platform framing was wrong. Sometimes it’s evidence you haven’t found the investor whose risk appetite matches your actual risk profile yet.
Here’s the uncomfortable synthesis: Appelhans, Mordwinkin, and Taffy were managing single-shot clinical risk in indications where a validated, near-term data readout was available and credible. Proving the asset first was the cheaper, faster, lower-risk way to earn the market’s attention, and pipeline credit followed naturally once it arrived. Stanicka was managing a different problem entirely: a platform she believed to be more valuable, and less replaceable, than any single indication it could produce, in a clinical area (psychiatric disease, following a difficult pivot out of spinal cord injury) where a narrow bet actually looked riskier than a broad one.
The failure mode on one side is obvious: a founder with a thin, unproven platform pitching pipeline potential before anyone has clinical data to hang it on. Investors have seen this pitch a thousand times and discount it correctly; Appelhans’s and Mordwinkin’s experience is the market’s answer to it.
The failure mode on the other side is less discussed but just as costly: a founder sitting on a genuinely differentiated platform who stays narrowly lead-asset-focused past the point of usefulness, because “prove it first” has become dogma rather than a strategy. That founder leaves the Stanicka outcome on the table. If your platform’s value is genuinely greater than the sum of a single indication, and you can defend that claim with more than enthusiasm, a single-asset story undersells the company and may attract the wrong investor base entirely: one that values you on a Phase 2 readout instead of on the thing you actually built.
Before your next raise, answer these questions honestly-ideally with your board, not just your bankers.
The platform premium is real. It’s just not a starting price. It’s a price investors pay after you’ve shown them why it should apply to you specifically, or, in rarer cases, after you’ve made an unusually convincing case that waiting for proof would have cost more than the risk of asking for belief up front. Know which company you are before you write the deck.
At Scimitar, Akira Robinson serves as Partner, Commercialization. He operates at the intersection of commercial strategy, launch execution, and market access, advising biopharma executive teams at critical moments where launch readiness directly determines asset value and time to market. With 20 years of experience across life sciences, diagnostics, biologics, and digital medicine, his work tackles complex commercial challenges for teams across the US and globally. His expertise spans the full commercial value chain—including launch planning, licensing, market access, pricing, analytics, marketing, sales distribution, and patient services across therapy areas, including: oncology, radiopharmaceuticals (RLT), rare disease, CNS, cardiology, and gastroenterology.
